Ocugen OCGN is entering a period where the stock can be driven more by calendar-based catalysts than traditional fundamentals. Multiple late-stage readouts and filing steps are lined up across its

Ocugen OCGN is pushing three retinal gene therapy programs toward late-stage milestones, with multiple data readouts and regulatory steps clustered into 2026 and early 2027. The setup makes the next

Vertex Pharmaceuticals Incorporated VRTX stock has declined 4.8% over the past month. This reflects concerns over the commercial potential of its new drugs, Journavx and Casgevy, recent pipeline

McKesson MCK reported strong third-quarter fiscal 2026 results, driven by robust growth in specialty distribution, oncology services and biopharma solutions. Continued operational efficiency and

BitFuFu Inc. (FUFU) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.14 per share a year ago. These figures

There are plenty of choices in the Large Cap Growth category, but where should you start your research? Well, one fund that might be worth investigating is T. Rowe Price Institutional Large Cap Core

Looking for a Sector - Finance fund? You may want to consider T. Rowe Price Financial Services (PRISX) as a possible option. PRISX holds a Zacks Mutual Fund Rank of 3 (Hold), which is based on

There are plenty of choices in the Index category, but where should you start your research? Well, one fund that might be worth investigating is Vanguard Total International Stock Index Fund

Having trouble finding a All Cap Value fund? Oakmark Investor (OAKMX) is a possible starting point. OAKMX holds a Zacks Mutual Fund Rank of 3 (Hold), which is based on various forecasting factors